Figure 5. PCaA-SEV delays tumor progression and enhances survival of prostate cancer bearing mice.
(A) Schema of TRAMP-C2 tumor cells administration and pMV101 or PCaA-SEV administration into C57BL/6 mice. Mice were administered subcutaneously 1.0 x 106 TRAMP-C2 cells. After TRAMP-C2 tumor challenge in C57BL/6 mice on day 0, mice were immunized with PCaA-SEV (50μg/immunization) on day 7, 21 and 35 through optimized EP enhanced delivery. (B) Assessment of tumor development in control plasmid (pMV101) and PCaA-SEV+TRAMP-C2 cells injected mice. Tumor volumes (mm3) were measured weekly, by a digital caliper, for up to 80 days post tumor administration in mice. Mice inoculated with PCaA-SEV plasmid exhibited delayed tumor growth, as evinced by tumor volume. (C) Kaplan–Meier survival curves of TRAMP-C2 prostate tumor bearing mice immunized with PCaA-SEV or pMV101 vector. Mice immunized with PCaA-SEV were found to exhibit improved survival compared to the pMV101 vaccinated mice.